| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Childrens Hospital of Pittsburgh (R.J.S., K.D., V.D.L., S.A.A.), Pittsburgh, Pennsylvania 15213; and Childrens Hospital (B.S.K.), Knoxville, Tennessee 37916
Address all correspondence and requests for reprints to: Silva Arslanian, M.D., Division of Endocrinology, Childrens Hospital of Pittsburgh, 3705 Fifth Avenue at DeSoto Street, Pittsburgh, Pennsylvania 15213. E-mail: arslans{at}chplink.chp.edu
Abstract
Puberty is characterized by temporary insulin resistance, which subsides with the completion of pubertal development. This insulin resistance is manifested by lower rates of insulin-stimulated glucose metabolism and compensatory hyperinsulinemia in pubertal compared with prepubertal children. Whether or not pubertal insulin resistance is the result of sex steroids or GH or a combination of both has been investigated in our laboratory. Previously, we demonstrated that T treatment in adolescents with delayed puberty was not associated with the deterioration of insulin action. The present investigation evaluated the effects of 4 months of dihydrotestosterone administration (50 mg im every 2 wk) on body composition, glucose, fat, and protein metabolism, and insulin sensitivity. Ten adolescents with delayed puberty were evaluated before and after 4 months of DHT administration. Body composition was assessed by dual energy x-ray absorptiometry. Insulin-stimulated glucose metabolism was measured during a 3-h hyperinsulinemic (40 mU/m2·min)-euglycemic clamp procedure. Lipolysis and proteolysis were evaluated by stable isotopes of [2H5]glycerol and [1-13C]leucine. After 4 months of dihydrotestosterone treatment, height, weight, and fat free mass increased and percentage of body fat decreased. IGF-I and nocturnal GH levels did not change. There was no significant change in insulin-stimulated glucose metabolism (57.2 ± 3.9 vs. 58.3 ± 3.9 µmol/kg·min). Total body proteolysis and lipolysis did not change. In summary, based on the present and past studies, we conclude that during puberty insulin resistance/hyperinsulinemia is not attributable to gonadal sex steroids in boys.
This article has been cited by other articles:
![]() |
C. M. Schooling, C. Q. Jiang, T. H. Lam, W. S. Zhang, K. K. Cheng, and G. M. Leung Life-Course Origins of Social Inequalities in Metabolic Risk in the Population of a Developing Country Am. J. Epidemiol., February 15, 2008; 167(4): 419 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Hannon, K. Danadian, C. Suprasongsin, and S. A. Arslanian Growth Hormone Treatment in Adolescent Males with Idiopathic Short Stature: Changes in Body Composition, Protein, Fat, and Glucose Metabolism J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3033 - 3039. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bacha, R. Saad, N. Gungor, and S. A. Arslanian Are Obesity-Related Metabolic Risk Factors Modulated by the Degree of Insulin Resistance in Adolescents? Diabetes Care, July 1, 2006; 29(7): 1599 - 1604. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Y. Liu, R. S. Swerdloff, and J. D. Veldhuis The Rationale, Efficacy and Safety of Androgen Therapy in Older Men: Future Research and Current Practice Recommendations J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4789 - 4796. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-L. Tsou, Y.-D. Jiang, C.-C. Chang, J.-N. Wei, F.-C. Sung, C.-C. Lin, C.-C. Chiang, T.-Y. Tai, and L.-M. Chuang Sex-Related Differences Between Adiponectin and Insulin Resistance in Schoolchildren Diabetes Care, February 1, 2004; 27(2): 308 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bacha, R. Saad, N. Gungor, and S. A. Arslanian Adiponectin in Youth: Relationship to visceral adiposity, insulin sensitivity, and {beta}-cell function Diabetes Care, February 1, 2004; 27(2): 547 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bacha, R. Saad, N. Gungor, J. Janosky, and S. A. Arslanian Obesity, Regional Fat Distribution, and Syndrome X in Obese Black Versus White Adolescents: Race Differential in Diabetogenic and Atherogenic Risk Factors J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2534 - 2540. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |